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Abstract We have been isolating and analyzing NRK cell
mutants, which fail to transform by epidermal growth factor
(EGF) and transforming growth factor (TGF)-L. One such
mutant, R14, can respond to the growth inhibitory signal of
TGF-L to the same extent as parental NRK but fail to respond to
the growth stimulatory signal of EGF. This mutant has a defect
in EGF receptor (EGFR) expression. When R14 mutant
expressed a high level of EGFR, however, EGF not only induced
proliferation in this mutant but also induced transformation
without the aid of TGF-L. These findings suggest that the major
role of TGF-L in this transformation system should be to
counteract the ligand-dependent down-regulation of EGFR,
thereby sustaining high-level EGF-signaling.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Transforming growth factor (TGF)-L is a multifunctional
peptide that controls proliferation, di¡erentiation, carcinogen-
esis, etc. (reviewed in [1,2]). TGF-L was originally isolated as a
factor capable of inducing a reversible phenotypic transforma-
tion of rat ¢broblasts [3,4]. TGF-L alone, however, does not
induce transformation but rather inhibits the growth of many
types of cells [2,5]. Since the TGF-L receptor genes were iso-
lated, intracellular pathways for TGF-L signal transduction
have partly been understood, and several biochemical targets
for TGF-L-induced growth inhibitory signals have been iden-
ti¢ed (reviews in [6,7]).
The possible involvement of TGF-L in general oncogenic
transformation has most extensively been studied with the
NRK-49F (NRK) cell line, since this cell line is reversibly
transformed by epidermal growth factor (EGF) in the pres-
ence of TGF-L [3]. To explore the mechanism of oncogenic
transformation, we have been studying NRK and its mutants
which fail to be transformed by EGF and TGF-L treatment
[8^12]. One such mutant, R14, has a defect in EGF receptor
(EGFR) expression but can be transformed by various onco-
genes including v-erbB (active form of EGFR), suggesting
that this mutant retains all the down-stream components nec-
essary to transmit EGFR signal. Forced expression of the
EGFR gene in this mutant not only restored its responsive-
ness to EGF but also induced TGF-L-independent transfor-
mation in the presence of EGF. Our study with R14 cells
provides evidence that the major role of TGF-L in this trans-
formation system is not direct modi¢cation of EGFR mole-
cule but to retain high-level expression of EGFR and that
there should be a subtle balance between such a growth-pro-
moting signal via EGFR and growth inhibitory components
of the TGF-L signal in NRK.
2. Materials and methods
2.1. Cells and mutant isolation
Cell culture and mutant isolation were done as described previously
[8,9,11]. If not indicated, the ¢nal concentrations of growth factors
used were 5 ng/ml for EGF and platelet-derived growth factor
(PDGF), and 0.5 ng/ml for TGF-L. The lines NER-1, 14ER-1 and
14ER-2 were egfr cDNA (rat) transfectants isolated and cloned from
NRK or R14.
2.2. Growth curve and assay for growth in soft agar, proliferation, focus
formation, 125I-hEGF-binding, GTPase and In-gel kinase
To determine growth curves, 100 cells were plated into a 60 mm
dish. Five di¡erent ¢elds of cells were photographed in each dish. The
same ¢elds of cells were photographed and counted every day. The
experiment was done in triplicate. Assays for growth in soft agar,
proliferation, focus formation and 125I-hEGF-binding, GTPase, In-
gel kinase were done as described previously [8,9,12].
2.3. DNA transfection and colony assay
DNA transfection was carried out as described previously [13]. Rat
egfr cDNA was isolated from NRK pcD2-cDNA library by colony
hybridization using human egfr cDNA as a probe. The plasmids used
are pcD2neo vector, pFBJ-2neo (v-fos), pZipneo-erbB (v-erbB),
SVori-8-16 (SV40 T), p3611EH (v-raf), pGA-FeSV (v-fes),
pSVerbBVE (activated c-erbB-2), and pSM-FeSV (v-fms). The trans-
fectants were selected in growth medium containing 400 Wg/ml G418
for 2 weeks. The numbers of transformed and £at antibiotics-resistant
colonies were scored separately.
2.4. Immunoprecipitation and immunoblot detection
EGFR was immunoprecipitated with an anti-EGFR antibody (Up-
state Biotechnology, Lake Placid, NY, USA) from cell lysate (1 mg
protein), electrophoresed on a 4^20% polyacrylamide gradient gel
(Daiichi pure chemicals), blotted onto a nitrocellulose ¢lter, and de-
tected with an anti-EGFR or anti-phosphotyrosine antibody (Trans-
duction Laboratories).
2.5. Analysis of the EGFR promoter
The genome DNAs were isolated from NRK and R14 mutant as
described [14]. Wild-type rat egfr promoter was isolated from NRK
genome by using Genome Walker kit (Clontech) from the SspI-di-
gested template. The PCR primers used for the promoter region am-
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pli¢cation were EGFR-p1 (TGA CTG CGT CGG CAA CGA CGA
CGG) and AP-1 primer (Clontech) for the ¢rst cycle, and EGFR-p2
(AGA CTC GCG TCC AGG TGA CCC GTC) and AP-2 primer
(Clontech) for the second cycle. EGFR-p1 and -p2 are located imme-
diately up-stream of the translation initiation codon. The ampli¢ed
fragment of about 1.5 kb was subcloned and sequenced. Based on the
sequence data, a new set of primers with £anking primer-binding site
for 340M13 or 321M13 primer of DYEnamic Energy Transfer for-
ward dye primer (underlined sequences) (Amersham) was prepared for
amplifying the promoter region of NRK and R14 mutant; EGFR-p3
(TGT AAA ACG ACG GCC AGT GCT CTA CAT TTC CAC AGC
TTC) located at 1.5 kb up-stream of EGFR-p1, EGFR-p4 (GTT TTC
CCA GTC ACG ACG TTC TCG CAG TCC CTG AGG GTC)
located near EGFR-p1, EGFR-p5 (GTT TTC CCA GTC ACG
ACG CAC TGC GCT GCA TTT CAG GAC C), and EGFR-p6
(TGT AAA ACG ACG GCC AGT CTC TGT GCC AGG AGT
TGG CTA CC). The ampli¢ed EGFR promoter regions were directly
sequenced.
3. Results
3.1. Isolation of R14 mutant
To study the molecular mechanism of oncogenic transfor-
mation, we isolated a series of NRK rat ¢broblast cell mu-
tants refractory to the transformation induced by treatment
with EGF plus TGF-L (E+T) [9^11]. One such mutant, R14,
was unable to form colonies in soft agar in response to E+T
(Fig. 1A), while it could be transformed by all the oncogenes
we tested: namely, v-erbB, c-erbB-2, v-ras, v-fms, v-mos, v-src,
v-fos, v-fes, SV40 T, polyoma virus middle T antigen (PyMT)
and v-raf (data not shown), indicating that this mutant retains
all the down-stream components necessary to transmit EGFR
signal. The R14 mutant grew more slowly than the parental
NRK cells and was not growth-stimulated by EGF (Fig. 1B).
The defect of R14 mutant was complemented by fusion with
parental NRK cells, indicating that the defect of R14 is re-
cessive (data not shown). The inability of R14 cells to respond
to the mitogenic activity of EGF seems rather speci¢c: EGF
failed to induce DNA synthesis in serum-starved R14 cells,
while PDGF and serum were fully active in this assay (Fig.
1C). Furthermore, when Ras and MAP-kinase in EGF-stimu-
lated R14 cells were examined by GTPase and in-gel kinase
assays, respectively, no activity was detected (data not
shown). All these data suggest that the defect in R14 mutant
is in EGFR itself.
3.2. R14 mutant has a defect in EGFR expression
We next estimated the amount of unoccupied EGFR on the
cell surface using an EGF-binding assay. The results clearly
indicated a marked reduction in the number of EGF-binding
sites on R14 cell surface (data not shown). Moreover, we
found that the EGFR protein and its mRNA were barely
detectable in R14 cells cultured in regular growth medium
(Fig. 2A,B), suggesting that the observed decrease in EGF-
binding was due to the decreased level of EGFR mRNA. The
time course analysis revealed that total EGFR protein is
quickly degraded in NRK cells after EGF addition, while
TGF-L markedly inhibited this e¡ect (Fig. 2C for the data
up to 4 h and Fig. 2B at 24 h). This can be explained by
the activity of TGF-L to increase the level of EGFR mRNA
(Fig. 2A). In R14 cells, the EGFR mRNA and its protein
product became detectable after 24 h TGF-L treatment (Fig.
2A,B).
When treated with TGF-L, R14 mutant was able to express
a low level of EGFR (Fig. 2A,B), which seems to be func-
tional because it was able to induce proliferative response
(Fig. 3B, R14/E+T). Because the sizes of mRNA and protein
of EGFR and the result of Southern blot analysis of R14 cells
were the same as parental NRK cells (Fig. 2A,B and data not
shown), we suspected that a defect of R14 mutant could be in
the promoter region of egfr gene that results in ine⁄cient
Fig. 1. Growth properties of the parental NRK line and R14 mu-
tant. (A) The growth of NRK and R14 cells in liquid (upper panels)
and soft agar (lower panels) cultures. (B) Growth curves. Increases
in the number of cells are presented as the ratio to the number at
day 1. Mean values from triplicate dishes are presented with S.E.M.
bars. (C) Proliferative response of R14 to growth factors. Each ex-
periment was done in triplicate and the average number of net cpm
was indicated with a S.E.M. bar.
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mRNA transcription and hence an attenuated response to
EGF. To examined the egfr promoters of R14 mutant, we
isolated an approximately 1.5 kb promoter region up-stream
of the initiation codon of egfr gene from both NRK and R14
cells. In human egfr promoter, this region contains the mini-
mal promoter (3140 to 320 relative to the translation initia-
tion codon) [15], p53-binding site (3265 to 3239) [16], and
TGF-L responsive element(s) (3919 to 3860) [17]. We found
the corresponding sequences to these regions in the NRK egfr
promoter (data not shown). We directly sequenced the pro-
moter regions and carefully compared the data from R14 and
NRK. However, we could not detect any di¡erence between
the two (data not shown).
3.3. Exogenous EGFR expression rescued the R14 defect
If the reduction in EGFR is solely responsible for the phe-
notype of R14 mutant, then the restored expression of EGFR
gene may complement its defect. When R14 cells were trans-
fected with a rat egfr cDNA inserted in pcD2 expression vec-
tor, approximately 10% of the transfected colonies became
responsive to EGF and transformed (Table 1). We usually
obtained approximately 10% of G418-resistant colonies (0.4
mg G418/ml), which express a relatively high level of an in-
serted gene in pcD2 vector [8,9]. We randomly picked up 10 of
these colonies and analyzed by Western blotting. All of these
clones were found to express several to 10-fold higher levels of
EGFR than the parental NRK cells (Fig. 4A and data not
shown). Two representative clones (R14ER-1 and -2) stably
expressing the transfected EGFR gene (Fig. 3A) were sub-
jected to further characterization. Both clones had restored
their ability to proliferate in response to EGF (Fig. 3B, striped
bars). They had also gained the ability to form colonies in soft
agar in response to EGF alone (Fig. 3C, dark bars). Unex-
pectedly, however, TGF-L showed rather negative e¡ects on
the EGF-induced growth stimulation as well as anchorage-
independent growth in these transfectant lines (Fig. 3B,
open bars; Fig. 3C, light bars). Interestingly, an EGFR trans-
fectant line derived from the parental NRK (NER-1) showed
a similar response to E+T (Fig. 3C), indicating that the un-
expected results with the R14-derived transfectants cannot be
attributed to some unusual property of this mutant.
3.4. Overexpression of EGFR induced TGF-L-independent
transformation
NER-1 cells showed a highly transformed morphology
when treated with EGF alone but less transformed morphol-
ogy when treated with E+T (Fig. 4A). Such a response is not
unique to this particular transfectant line, because freshly
transfected NRK cells also showed a similar tendency of re-
sponse to EGF and E+T when individual colonies were ex-
Fig. 2. E¡ects of EGF and TGF-L on the expression of EGFR. (A)
Northern blot analysis of egfr mRNA in NRK and R14 cells. Cells
cultured with or without TGF-L for 24 h were harvested, and poly-
(A) RNA was prepared. 5 Wg of each RNA sample was subjected
to Northern blot hybridization. EGFR mRNAs were detected as
one major (9.6 kb) and two minor (6.5 and 5.0 kb) bands as previ-
ously reported by Petch et al. [40]. Glyceraldehyde-3-phosphate de-
hydrogenase (GAPD) mRNA was shown as an internal standard.
(B) Detection of EGFR protein in NRK and R14 cells. Cells were
cultured for 24 h either in serum-free medium (none), regular
growth medium (FCS), or growth medium containing EGF (EGF),
TGF-L (TGF-L), or EGF plus TGF-L (E+T). The cell lysates were
prepared and used to detect EGFR expression by immunoprecipita-
tion followed by immunoblot detection. (C) Time course of EGFR
down-regulation in NRK cells. Sub-con£uent NRK cells were cul-
tured in serum-free medium for 2 days and then, EGF was added
to each culture. In E+T, TGF-L was added into the culture 8 h pri-
or to the addition of EGF. After the indicated time of incubation,
the cells were lysed, and EGFR was immunoprecipitated and ana-
lyzed by immunoblot detection.
Table 1
E¡ects of EGF and TGF-L on the morphology of egfr-transfected
cells
Cells No. of transformed colonies/
No. of total colonies (%)
NRKneo (E) Expt.1 50/3450 (1.4%)
Expt.2 42/2820 (1.5%)
(E+T) Expt.1 2900/2950 (98.3%)
Expt.2 2750/2820 (97.5%)
NRK-EGFR (E) Expt.1 290/653 (44.4%)
Expt.2 262/643 (40.7%)
(E+T) Expt.1 79/451 (17.5%)
Expt.2 62/436 (14.1%)
R14neo (E) Expt.1 0/4630 (6 0.02%)
Expt.2 0/2300 (6 0.04%)
(E+T) Expt.1 0/2720 (6 0.04%)
Expt.2 0/2770 (6 0.04%)
R14-EGFR (E) Expt.1 20/219 (9.1%)
Expt.2 18/173 (10.4%)
(E+T) Expt.1 4/186 (2.1%)
Expt.2 8/278 (2.9%)
NRK-EGFR, R14-EGFR, NRKneo and R14neo are NRK or R14
transfectants of rat egfr cDNA (-EGFR) or pcD2 empty vector
(neo). The transfectants were selected in G418-containing growth
medium for 3 weeks and then cultured with the medium containing
5 ng EGF/ml (E) or 5 ng EGF/ml plus 0.5 ng/ml TGF-L (E+T) for
5 days, and then their morphology was examined under a micro-
scope. None of the transfectants was transformed in regular growth
medium.
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amined (Table 1). Since TGF-L did not a¡ect the viability
(data not shown), the negative e¡ects of TGF-L cannot be
explained by cell death. The negative e¡ect of TGF-L has
been observed in growth with regular growth medium. The
parental NRK cells grow slower with E+T than with EGF
alone (Fig. 4B). This tendency is more signi¢cant in NER-1
cells (Fig. 4B). Together, these results suggest that the growth
and transforming properties of NRK cells regulated by E+T
can be explained by a somehow deviated balance between the
positive and negative components of the TGF-L signal in
NRK cell line.
4. Discussion
TGF-L was originally identi¢ed as one of the factors that
were secreted from transformed cells and induced malignant
transformation of NRK cells when added to medium [18].
Later studies, however, demonstrated that TGF-L inhibits
the growth of various types of cells [19^22] and suggest that
TGF-L may be better conceived as a tumor suppressor rather
than a tumor inducer [22^25]. In fact, inactivating mutations
of the genes involved in the intracellular signaling for TGF-L
(i.e. TGF-L receptors and Smad proteins) have been found in
multiple types of human cancers [26^31]. Thus, the oncogenic
stimulation of NRK by TGF-L remained to be an interesting
paradox.
In 1988, Thompson et al. [32] reported that TGF-L induces
the expression of EGFR in this cell line. We independently
made a similar observation during this study. These ¢ndings
raised the possibility that TGF-L sensitizes NRK cells to the
mitogenic activity of EGF by augmenting the expression of
Fig. 3. E¡ects of egfr gene overexpression on the growth properties
of NRK and R14 cells. (A) EGFR expression in NRK, R14 and
their egfr transfectants. Total lysate (5 Wg) of A431 cells was used
as a positive control. Cells were serum-starved for 2 days and then
treated with EGF for 3 min. The cell lysates were prepared, and
EGFR protein was immunoprecipitated with anti-hEGFR and ana-
lyzed by immunoblot detection with anti-EGFR (upper panel) or
anti-phosphotyrosine (K P-Tyr) (lower panel) antibody. (B) Prolifer-
ative response of egfr transfectants of R14. Mean values from tripli-
cate experiments are presented with S.E.M. bars. (C) Growth of
NRK, R14 and their egfr transfectants in soft agar. Cells were inoc-
ulated into semi-solid medium containing EGF at the ¢nal concen-
tration of 5 (E5), 50 (E50) or 100 (E100) ng/ml with (+T) or with-
out 0.5 ng/ml TGF-L. % CV is less than 3.0.
Fig. 4. E¡ects of TGF-L on the phenotype of egfr overexpressing
NRK cells. (A) NER-1 cells were cultured in regular growth me-
dium (none) or the medium containing EGF or E+T for 1 week
(upper panels). NER-1 cells were inoculated into soft agar contain-
ing indicated growth factor(s) and incubated for 2 weeks (lower
panels). (B) Growth curves. See Fig. 1B for detail.
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EGFR. On the other hand, it has been suggested that TGF-L
may directly modify EGFR molecule itself in phosphorylation
and alter its a⁄nity to EGF [33,34]. Our study on R14 mutant
has provided a support that TGF-L could induce cell trans-
formation, only if the expression of EGFR can be inducible
over a su⁄cient level. The growth of R14 mutant is, however,
strongly inhibited as well as parental NRK cells when TGF-L
alone is added to the medium, suggesting that the growth
inhibitory signal of TGF-L is transduced through an inde-
pendent cascade of the oncogenic growth stimulatory signal.
The growth inhibitory e¡ect of TGF-L was also observed in
the transformed cells culturing in liquid and semi-solid me-
dium (Figs. 3B,C, 4B and Table 1). It is intriguing to spec-
ulate that there may be bi-directional, positive and negative
cross talks between EGF- and TGF-L-signaling pathways and
that growth of the cells may be regulated by the net balance of
these positive and negative signals. In such system, the e¡ects
of a particular signal may become evident only when cells are
placed under extreme conditions, for instance, overexpression
of a single component of the pathways.
We still do not know exactly which gene is mutated in R14
cells. R14 is a recessive mutant and the only di¡erence we
found between R14 and parental NRK is in the expression
of EGFR. The sequencing analysis revealed that there was no
mutation in the cis-regulatory elements of this region in R14
mutant. So a defect should be in a certain trans-regulatory
element for the egfr promoter or in a certain crucial cis-ele-
ment for post-transcriptional regulation. Further analysis of
R14 cells is needed to identify the mutation.
This study revealed that the strong EGF signal is necessary
and su⁄cient for the transformation in this system and TGF-
L plays the role of sustaining high EGFR expression. EGF-
induced transformation is not speci¢c to the NRK cells over-
expressing EGFR. NIH/3T3 cells overexpressing EGFR can
also be transformed in a ligand-dependent manner [35]. Over-
expression of EGFR is frequently found in naturally occur-
ring tumors [36^39]. The experimental data, including ours,
clearly indicate a signi¢cant impact of EGFR overexpression
on malignant transformation: EGFR overproduction would
dramatically increase the chance for the cells to receive mito-
genic EGF signals continuously and to accumulate mutations
in other genes critical for malignant progression. Further
characterization of R14 mutant may yield important insights
into the regulatory mechanisms of egfr gene expression and
may help developing a new approach to the treatment of
certain types of cancer.
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